US Equities Analysis

ZTS — Zoetis

ZTS Price Chart FCF Yield Dividend Yield Price / Earnings Price / Book EV / EBITDA EV / NOPAT Consensus EPS Broker Sentiment EBITDA Margin EBIT Margin ROIC & ROE Capital Turnover Capex & WC / Sales Net Debt / Equity Price and 100d MA Relative to Index Relative to MSCI


1. Industry Fundamentals

1.1 Cyclicality

The company operates in a cyclical industry sensitive to macroeconomic conditions. Revenue and earnings tend to correlate with broader economic cycles, with periods of expansion driving growth and contractions creating headwinds. Current market capitalisation: 34.08B.

1.2 Competition

The industry is moderately competitive with established players and meaningful barriers to entry. Beta of 0.74 suggests moderate market sensitivity. Competitive advantages stem from brand, scale, or regulatory moats.

1.3 Technology

Key technology drivers include digital transformation, operational efficiency, automation. Companies that invest in R&D and adopt new technologies tend to gain market share. The pace of technological change creates both opportunities for innovation and risks of disruption.


2. Company Fundamentals

2.1 Competitiveness

Metric Value
Operating Margins 36.56%
Profit Margins 28.04%
Return on Equity 67.75%
Return on Assets 15.53%
Free Float 0.42B
Dividend Yield 2.72%
Short Int % Utilisation 3.63%

2.2 Growth

Metric Value
Revenue Growth 2.9%
Free Cash Flow 1.78B
EBITDA 10.16 (Ratio)
Enterprise Value 41.39B
EV/Revenue 4.34
EV/EBITDA 10.16

Revenue growth of 2.9% suggests mature or challenged top-line momentum.

2.3 Management

Role Metric
Consensus Rating N/A

2.4 Return

Metric Value
Expected Return (Ann.) -10.95%
Risk / Std Dev (Ann.) 28.78%
Sharpe Ratio (rf=4.5%) -0.54
Beta 0.74

2.5 Valuation

Metric Value
P/E (Forward) 10.95
Price/Book 9.80
EV/Revenue 4.34
EV/EBITDA 10.16
Enterprise Value / NOPAT 12.28
FCF Yield (%) 5.53%
Price / Earnings 12.60
Price / Book 9.80
Enterprise Value / EBITDA 9.70

Forward P/E of 11x is within a reasonable range for the company’s peer group.

2.6 Return Outlook

The stock’s historical risk-return profile shows an annualised expected return of -10.9% with annualised volatility of 28.8%, yielding a Sharpe ratio of -0.54 (rf=4.5%). The risk-adjusted return is below the risk-free rate, suggesting compensation for risk may be inadequate. With a beta of 0.7, the stock is less volatile than the market, offering relative downside protection.


us-equitystockequityztshealth-carepharmaceuticalsnasdaq